Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.49 |
| ▸ | ACACA | Q13085 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.41 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.40 |
| ▸ | CDK2AP1 | O14519 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4293983 | 0.90 | ACACB (0.57) | ACACBACACAMEN1KMT2ACHEK1 | |
| SCHEMBL4295251 | 0.90 | ACACB (0.45) | ACACBACACAMEN1KMT2AMCHR1 | |
| SCHEMBL13609473 | 0.90 | ACACB (0.45) | ACACBACACAMEN1KMT2AMCHR1 | |
| SCHEMBL4297088 | 0.88 | ACACB (0.51) | ACACBACACAMEN1KMT2AMCHR1 | |
| SCHEMBL4294112 | 0.84 | CHEK1 (0.56) | ACACBACACAMEN1KMT2ACHEK1 | |
| SCHEMBL4297323 | 0.83 | ACACB (0.54) | ACACBACACAMEN1KMT2AEPHX2 | |
| SCHEMBL13609471 | 0.81 | ACACB (0.51) | ACACBACACAMEN1KMT2ACHEK1 | |
| SCHEMBL4294377 | 0.81 | ACACB (0.52) | ACACBACACAMEN1KMT2ACHEK1 | |
| SCHEMBL4298592 | 0.79 | ACACB (0.59) | ACACBACACAMEN1KMT2AABCC1 | |
| SCHEMBL6183549 | 0.78 | ACACB (0.53) | ACACBACACAMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-2009011-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TNNC1, CPT1B, TNNI3 | ACACB 23/4885ACACA 12/4885MEN1 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.